Portal de Periódicos da CAPES

Cardiopulmonary Toxicity after Liposomal Amphotericin B Infusion

1991; American College of Physicians; Volume: 114; Issue: 8 Linguagem: Inglês

10.7326/0003-4819-114-8-664

1539-3704

Stewart J. Levine, Thomas J. Walsh, Anthony Martinez, Peter Q. Eichacker, Gabriel Lopez‐Berestein, Charles Natanson,

Cystic Fibrosis Research Advances

Brief Reports15 April 1991Cardiopulmonary Toxicity after Liposomal Amphotericin B InfusionStewart J. Levine, MD, Thomas J. Walsh, MD, Anthony Martinez, MD, Peter Q. Eichacker, MD, Gabriel Lopez-Berestein, MD, Charles Natanson, MDStewart J. Levine, MD, Thomas J. Walsh, MD, Anthony Martinez, MD, Peter Q. Eichacker, MD, Gabriel Lopez-Berestein, MD, Charles Natanson, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-8-664 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptLiposomal and lipid-complex drug delivery systems are being developed to enhance the therapeutic activity, decrease the toxicity, and provide site-specific delivery of high doses of amphotericin B (1-3). Incorporation within liposomes is thought to produce lipid-stabilized, ribbon-like amphotericin B aggregates that may decrease toxicity by allowing selective transfer of the drug directly to ergosterol-containing fungal cell membranes (4). Toxic reactions associated with liposomal amphotericin B (L-AmpB) therapy in humans have included fever, chills, nausea, and electrolyte disturbances (5-7). This report supplements the known toxicities by describing reversible abnormalities in pulmonary gas exchange and cardiopulmonary hemodynamics in a patient receiving high-dose...References1. WiebeDeGregorio VM. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev Infect Dis. 1988;10:1097-101. CrossrefMedlineGoogle Scholar2. Sarosi G. Nosocomial amphotericin B: current status [Editorial]. Arch Intern Med. 1989;149:2402-3. CrossrefMedlineGoogle Scholar3. Lopez-Berestein G. Liposomal amphotericin B in the treatment of fungal infections. Ann Intern Med. 1986;105:130-1. LinkGoogle Scholar4. JanoffBoniPopescu ALM. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA. 1988;85:6122-6. CrossrefMedlineGoogle Scholar5. Lopez-BeresteinFainsteinHopfer GVR. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985;151:704-10. CrossrefMedlineGoogle Scholar6. Lopez-BeresteinBodeyFrankelMehta GGLK. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987;5:310-7. CrossrefMedlineGoogle Scholar7. Lopez-BeresteinBodeyFainstein GGV. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989;149:2533-6. CrossrefMedlineGoogle Scholar8. MiyamotoSchultzHeathMitchellAlbertineStaub KETMKN. Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. J Appl Physiol. 1988;64:1143-52. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From the National Institutes of Health, Bethesda, Maryland; and the University of Texas M. D. Anderson Cancer Center, Houston, Texas. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOne Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting TherapyPreparation and In Vitro Evaluation of Alginate Microparticles Containing Amphotericin B for the Treatment of Candida InfectionsPEGylated liposomes: immunological responsesLiposomal Amphotericin B–Associated Cardiac ArrestImmune Response to PEGylated Nanomedicines: Impact of IgM ResponseDLI Induced by Antiarrhythmic Drug and Antimicrobial Drug: What Are the Characteristics of DLI in Antiarrhythmic Drugs and Antimicrobial Drugs?Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric PatientsDrug-Induced Pulmonary DiseaseImmediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusionToxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin BCUMULATIVE CARDIAC TOXICITY OF SODIUM STIBOGLUCONATE AND AMPHOTERICIN B IN TREATMENT OF KALA-AZARHypersensitivity Reactions to Nanomedicines: Causative Factors and Optimization of Design ParametersDrug-Induced Pulmonary DiseaseAcute Amphotericin B OverdoseActivation of the Human Complement System by Cholesterol-Rich and PEGylated Liposomes—Modulation of Cholesterol-Rich Liposome-Mediated Complement Activation by Elevated Serum LDL and HDL LevelsComplement activation-related pseudoallergy: A new class of drug-induced acute immune toxicityLiposome OpsonizationComplement Activation-Related PseudoallergyAmphotericin B lipid complex for the treatment of invasive fungal infectionsTriad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological CharacteristicsProtection by Tetracyclines against Ion Transport Disruption Caused by Nystatin in Human Airway Epithelial CellsPulmonary Reactions during Treatment with Amphotericin B: Review of Published Cases and Guidelines for ManagementAmphotericin B — Not So TerribleLiposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reactionPrevention of the Hemodynamic Effects of Iopromide-Carrying Liposomes in Rats and PigsChest and Back Pain Associated with a Six-Hour Infusion of Liposomal DaunorubicinDrug-Induced Respiratory DisordersPharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsionHemodynamic Changes Induced by Liposomes and Liposome-Encapsulated Hemoglobin in PigsAmphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 casesLiposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaComplement-Mediated Acute Effects of Liposome-Encapsulated HemoglobinDrug Delivery Systems for Infection: Liposome-Incorporating Antimicrobial DrugsClinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug DevelopmentPoly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicityInterferon-associated left ventricular dysfunction in a liver transplant recipientRECENT PROGRESS AND CURRENT PROBLEMS IN TREATMENT OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTSExogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activityComparison of three treatment regimens with liposomal amphotericin B (AmBisome®) for visceral leishmaniasis in India: a randomized dose-finding studyLiposomal Aerosols in the Management of Pulmonary InfectionsAerosolized Am B isome Treatment of Pulmonary Cryptococcus neoformans Infection in MiceAmphotericin B Toxicity Reduced by Administration in Fat EmulsionNew antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseasesPulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemiaToxic effects of antileishmanial reverse-phase evaporation liposomes containing dicetyl phosphate in monkeysDrug-induced pulmonary diseaseAntifungal agents: An overview. Part ILeishmaniose viscérale : actualités thérapeutiquesRESPIRATORY FAILURE AS A RESULT OF DRUGS, OVERDOSES, AND POISONINGSTreatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micellesAmphotericin B and its delivery by liposomal and lipid formulationsAmphotericin B Overdose in Pediatric Patients with Associated Cardiac ArrestClinical Experience with Multilamellar Liposomal Amphotericin B in Patients with Proven and Suspected Fungal InfectionsReduced Amphotericin Toxicity in an Albumin VehicleAerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in miceDrug-induced Pulmonary DiseaseLiposomes as Safe Carriers of Drugs and VaccinesAntifungal drugs 15 April 1991Volume 114, Issue 8Page: 664-666KeywordsAmphotericinCritical careDrugsFeversHemodynamicsHyperthermiaInfectious diseasesLiposomesNauseaToxicity Issue Published: 15 April 1991 PDF downloadLoading ...